Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Oncternal Therapeutics, Inc
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05431179CT.gov A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
NCT05744037CT.gov Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells | — | Unknown | — | — | — |
NCT03478514CT.gov Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03424122CT.gov INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) | — | Completed | — | — | — |
NCT03198026CT.gov Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas | — | Active Not Recruiting | — | — | — |
NCT03229200CT.gov Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | — | Active Not Recruiting | — | — | — |
NCT02950220CT.gov Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02670317CT.gov Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. | — | Terminated | — | — | — |
NCT02332980CT.gov Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas | — | Completed | — | — | — |
NCT02207062CT.gov Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma | — | Completed | — | — | — |
Show 6 more trialsShow fewer
NCT02055924CT.gov Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas | — | Terminated | — | — | — |
NCT01980654CT.gov Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma | — | Completed | — | — | — |
NCT01980628CT.gov Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma | — | Completed | — | — | — |
NCT01569750CT.gov A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma | — | Completed | — | — | — |
NCT01109069CT.gov Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia | — | Completed | — | — | — |
NCT00849654CT.gov Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · B-Cell Non-Hodgkin Lymphoma
+42 more in the B-Cell Non-Hodgkin Lymphoma cohort
Other indications for Ibrutinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lymphoid Leukemia | — | P4 | BBB · 72 |
| Waldenstrom Macroglobulinemia | — | P4 | BB · 70 |
| B-Cell Chronic Lymphocytic Leukemia | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ibrutinib in B-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ibrutinib-b-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →